Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies.
There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients.
The VANGUARD project aims to generate a vascularized and immune-protected bioartificial pancreas that can be transplanted into non-immuno-suppressed patients by combining advanced tissue engineering strategies.
This approach will yield a cell therapy in the form of an Advanced Therapy Medicinal Product (ATMP), which can significantly improve treatment of type 1 diabetes.
On Monday, 16th December 2024, VANGUARD partners from the Transplantation Department at Lyon Claude Bernard University and Edouard Herriot University Hospital participated in the 6th Lyon Immunopathology Federation (LIFe) seminar
Today, on World Diabetes Day, we emphasise the importance of open communication with patients and advocacy groups. Each November, VANGUARD partners connect, listen, and share progress with our community. This
A new VANGUARD article titled “The bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals in the Netherlands” has been published in the Journal of Clinical & Translational
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 874700